Beyond Preemption of Generic Drug Claims | Resources | Robins Kaplan LLP Law Firm

2015

Read the full article (PDF) >

Recent research indicates that the current cost of generic medications in the United States is the highest in history. Many patients are no longer able to afford life saving medications that were once affordable only five years ago. Concurrent to the rising prices of generic drugs, pharmaceutical companies have lauded preemption as a necessary and viable solution to combat the increasing prices. Two recent Supreme Court decisions, PLIVA, Inc. v. Mensing and Mutual Pharmaceutical Co. v. Bartlett, have agreed with this logic, and have attempted to pervert the Hatch-Waxman Act, and its corresponding ANDA approval process to shield generic drug manufacturers from liability.

Recent research indicates that the current cost of generic medications in the United States is the highest in history.

+ READ MORE - READ LESS

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.

Disclaimer

45 Sw. L. Rev. 241

Eric M. Lindenfeld

Associate

March 27, 2020

A Guide To Zealously Representing Clients During COVID-19

Anne Lockner - Law360

March 27, 2020

Coronavirus Aid, Relief, and Economic Security Act

Adam Mendel

Spring 2020

Estate Planning for Settlements or Favorable Verdicts

Matthew Frerichs and Sarah Khoury - The Robins Kaplan Spotlight, Vol. 5, No. 1

March 27, 2020

Navigating the USPTO During the COVID-19 Pandemic

Reena Jain

Spring 2020

Picking Your Team: Getting the Right Trustee or Personal Representative Appointed in a Wrongful Death Case

Teresa Fariss McClain and Timothy Billion - The Robins Kaplan Spotlight, Vol. 5, No. 1

VIEW ALL

March 24, 2020

Attorneys, Firm Recognized by Managing Intellectual Property

March 3, 2020

Kellie Lerner Named Antitrust and Trade Regulation Group Co-Chair

March 2, 2020

Robins Kaplan LLP Announces 2020 Executive Board

February 24, 2020

Robins Kaplan LLP Partners with University of South Dakota for Annual Moot Court Competition

February 20, 2020

Robins Kaplan LLP and Partner Hollis Salzman Named Finalists for Global Competition Review’s 2020 Antitrust Awards

VIEW ALL

Back to Top

Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.

If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.

By accepting these terms, you are confirming that you have read and understood this important notice.